OBJECTIVES: Myeloperoxidase (MPO) polymorphism -463 has been related to higher cardiovascular risk. This study was conducted to test whether the MPO promoter polymorphism -463A/G and MPO plasma levels are associated with coronary artery disease (CAD) severity. DESIGN AND METHODS: Patients submitted to elective coronariography were enrolled, CAD severity was assessed and blood samples collected to identify the MPO polymorphism and its plasma levels. RESULTS: Genotypes were determined in 118 patients. Among these patients, 12 (10%) were homozygous for AA, 69 (58%) for GG and 37 (32%) were heterozygous. Mean MPO plasma levels were 8.6+/-4.7 ng/mL for AA, 8.6+/-7.0 ng/mL for AG and 9.4+/-5.6 ng/mL for GG genotypes. The CAD severity was not associated with MPO genotypes (p=0.43), however, patients with higher CAD score presented higher MPO levels (p=0.02). CONCLUSION: We found no association between MPO polymorphism and CAD severity, although a relation was observed for MPO plasma levels and extension of CAD. Copyright 2009. Published by Elsevier Inc.
OBJECTIVES:Myeloperoxidase (MPO) polymorphism -463 has been related to higher cardiovascular risk. This study was conducted to test whether the MPO promoter polymorphism -463A/G and MPO plasma levels are associated with coronary artery disease (CAD) severity. DESIGN AND METHODS: Patients submitted to elective coronariography were enrolled, CAD severity was assessed and blood samples collected to identify the MPO polymorphism and its plasma levels. RESULTS: Genotypes were determined in 118 patients. Among these patients, 12 (10%) were homozygous for AA, 69 (58%) for GG and 37 (32%) were heterozygous. Mean MPO plasma levels were 8.6+/-4.7 ng/mL for AA, 8.6+/-7.0 ng/mL for AG and 9.4+/-5.6 ng/mL for GG genotypes. The CAD severity was not associated with MPO genotypes (p=0.43), however, patients with higher CAD score presented higher MPO levels (p=0.02). CONCLUSION: We found no association between MPO polymorphism and CAD severity, although a relation was observed for MPO plasma levels and extension of CAD. Copyright 2009. Published by Elsevier Inc.
Authors: Alexander P Reiner; Jaana Hartiala; Tanja Zeller; Joshua C Bis; Josée Dupuis; Myriam Fornage; Jens Baumert; Marcus E Kleber; Philipp S Wild; Stephan Baldus; Suzette J Bielinski; João D Fontes; Thomas Illig; Brendan J Keating; Leslie A Lange; Francisco Ojeda; Martina Müller-Nurasyid; Thomas F Munzel; Bruce M Psaty; Kenneth Rice; Jerome I Rotter; Renate B Schnabel; W H Wilson Tang; Barbara Thorand; Jeanette Erdmann; David R Jacobs; James G Wilson; Wolfgang Koenig; Russell P Tracy; Stefan Blankenberg; Winfried März; Myron D Gross; Emelia J Benjamin; Stanley L Hazen; Hooman Allayee Journal: Hum Mol Genet Date: 2013-04-24 Impact factor: 6.150
Authors: Eraldo de Azevedo Lucio; Sandro C Gonçalves; Jorge P Ribeiro; Gilberto L Nunes; Jarbas R de Oliveira; Gustavo N Araujo; Marco V Wainstein Journal: Inflamm Res Date: 2010-09-17 Impact factor: 4.575
Authors: Hubert Scharnagl; Marcus E Kleber; Bernd Genser; Sandra Kickmaier; Wilfried Renner; Gisela Weihrauch; Tanja Grammer; Christine Rossmann; Bernhard R Winkelmann; Bernhard O Boehm; Wolfgang Sattler; Winfried März; Ernst Malle Journal: Int J Cardiol Date: 2014-04-03 Impact factor: 4.164